On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial ...

Shares of Novocure Ltd. skyrocketed over 55% on Monday afternoon, reaching levels last seen in August 2023, as the company ...

Kelsey et al. compared the common chemotherapeutic combination of cisplatin and fluorouracil (5-FU) with a paclitaxel-based regimen. Previous studies have shown pathologic complete response rates ...

Novocure (NASDAQ:NVCR) has met the primary endpoint of overall survival in a late-stage trial evaluating the use of its Tumor ...

Novocure (NVCR) announced that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant ...

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer ...

Zai Lab (ZLAB) and Novocure (NVCR) announced that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically ...

Novocure’s TTFields therapy combined with chemo improved overall survival by 16.2 months compared to 14.16 months with chemo ...

The Phase I trial of the combination therapy has seen an approximate 66% rate of near-complete remission in its cohort of ...

Th e GINECO trial explored the combination of trastuzumab with paclitaxel and carboplatin in patients with resistant AOC (< 6 months) and HER2 gene amplification. Patients and Methods: A total of ...

Findings from the HELEN-006 trial suggest a potential shift in neoadjuvant treatment practices for patients with HER2-positive early breast cancer, specifically using nab-paclitaxel to reduce ...